PL1907000T3 - Metody i mieszaniny do leczenia infekcji przewlekłych - Google Patents

Metody i mieszaniny do leczenia infekcji przewlekłych

Info

Publication number
PL1907000T3
PL1907000T3 PL06784684T PL06784684T PL1907000T3 PL 1907000 T3 PL1907000 T3 PL 1907000T3 PL 06784684 T PL06784684 T PL 06784684T PL 06784684 T PL06784684 T PL 06784684T PL 1907000 T3 PL1907000 T3 PL 1907000T3
Authority
PL
Poland
Prior art keywords
pathway
inhibiting
compositions
treatment
methods
Prior art date
Application number
PL06784684T
Other languages
English (en)
Other versions
PL1907000T5 (pl
Inventor
Gordan Freeman
Arlene Sharpe
David M Dorfman
Rafi Ahmed
Daniel Barber
E John Wherry
Original Assignee
Dana Farber Cancer Inst Inc
Brigham & Womens Hospital Inc
Univ Emory
The President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1907000(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Brigham & Womens Hospital Inc, Univ Emory, The President And Fellows Of Harvard College filed Critical Dana Farber Cancer Inst Inc
Publication of PL1907000T3 publication Critical patent/PL1907000T3/pl
Publication of PL1907000T5 publication Critical patent/PL1907000T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
PL06784684T 2005-06-08 2006-06-08 Metody i kompozycje do leczenia infekcji przetrwałych PL1907000T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68887205P 2005-06-08 2005-06-08
PCT/US2006/022423 WO2006133396A2 (en) 2005-06-08 2006-06-08 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
EP06784684.0A EP1907000B2 (en) 2005-06-08 2006-06-08 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway

Publications (2)

Publication Number Publication Date
PL1907000T3 true PL1907000T3 (pl) 2013-05-31
PL1907000T5 PL1907000T5 (pl) 2020-11-16

Family

ID=37499143

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06784684T PL1907000T5 (pl) 2005-06-08 2006-06-08 Metody i kompozycje do leczenia infekcji przetrwałych
PL11162681T PL2397156T3 (pl) 2005-06-08 2006-06-08 Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11162681T PL2397156T3 (pl) 2005-06-08 2006-06-08 Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1)

Country Status (24)

Country Link
US (4) US8652465B2 (pl)
EP (5) EP2397155B1 (pl)
JP (7) JP5788632B2 (pl)
KR (4) KR101600225B1 (pl)
CN (3) CN103830725A (pl)
AU (1) AU2006254902B8 (pl)
BR (1) BRPI0611766A2 (pl)
CA (2) CA2981431C (pl)
CY (1) CY1118612T1 (pl)
DK (2) DK1907000T4 (pl)
ES (2) ES2608316T3 (pl)
HK (1) HK1115326A1 (pl)
HU (1) HUE030877T2 (pl)
IL (5) IL187999A (pl)
LT (1) LT2397156T (pl)
MX (2) MX349137B (pl)
NZ (4) NZ564243A (pl)
PL (2) PL1907000T5 (pl)
PT (1) PT2397156T (pl)
RU (3) RU2596491C2 (pl)
SG (1) SG10201702670VA (pl)
SI (2) SI1907000T2 (pl)
WO (1) WO2006133396A2 (pl)
ZA (1) ZA200710975B (pl)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014557A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2001014556A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
NZ564243A (en) 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
AR062419A1 (es) * 2006-08-21 2008-11-05 Hoffmann La Roche Terapia tumoral con un anticuerpo anti- vegf
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2014268176B2 (en) * 2006-12-27 2016-03-31 Dana-Farber Cancer Institute, Inc Compositions and methods for the treatment of infections and tumors
CN101663323A (zh) * 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
AU2013200388B2 (en) * 2006-12-27 2014-10-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
AU2007339762B2 (en) * 2006-12-27 2011-03-31 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
EP2535354B1 (en) * 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
AU2008293885A1 (en) 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8916596B2 (en) 2008-07-24 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110223188A1 (en) * 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US20110287034A1 (en) * 2008-11-14 2011-11-24 The Brigham And Womens Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
CA2744449C (en) * 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
KR20210060670A (ko) * 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
CN107090437A (zh) * 2009-03-06 2017-08-25 国立大学法人三重大学 用于增强t细胞功能的方法
WO2010106051A1 (en) * 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
PL2482849T3 (pl) * 2009-09-30 2018-11-30 Memorial Sloan-Kettering Cancer Center Skojarzona immunoterapia w leczeniu nowotworu
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
EP2531855A4 (en) * 2010-02-04 2013-08-07 Virostatics Srl KI-67 ASSAY FOR DETERMINING THE STATUS OF A PATIENT'S IMMUNE SYSTEM
CA2790134A1 (en) * 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
ES2888651T3 (es) * 2011-07-29 2022-01-05 Univ Pennsylvania Receptores de conmutación coestimulantes
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
KR102225422B1 (ko) 2011-09-30 2021-03-08 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
WO2013086133A1 (en) 2011-12-06 2013-06-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG11201404711WA (en) 2012-02-16 2014-09-26 Vlp Therapeutics Llc Virus like particle composition
WO2013155493A1 (en) 2012-04-12 2013-10-17 Yale University Methods of treating inflammatory and autoimmune diseases and disorders
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20150079192A1 (en) * 2012-05-21 2015-03-19 Marv Enterprises, LLC Treatment of cancer by manipulating the immune system
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014039983A1 (en) * 2012-09-07 2014-03-13 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
WO2014022758A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
JP2016505843A (ja) 2012-12-19 2016-02-25 アンプリミューン， インコーポレイテッド Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法
WO2014122271A1 (en) 2013-02-07 2014-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP4356960A2 (en) 2013-03-15 2024-04-24 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
WO2015038538A1 (en) * 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN107011441B (zh) * 2013-09-13 2020-12-01 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
JP6845691B2 (ja) 2013-11-01 2021-03-24 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法のための調節粒子
AU2014360273A1 (en) * 2013-12-06 2016-06-02 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
JP6590810B2 (ja) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
JP2017510631A (ja) 2014-03-14 2017-04-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
RU2735958C2 (ru) 2014-06-19 2020-11-11 Регенерон Фармасьютикалз, Инк. Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированной гибели клеток
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
CA2954841A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
JP6843736B2 (ja) 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
DK3177644T3 (da) 2014-08-05 2021-01-11 MabQuest SA Immunologiske reagenser, som binder til PD-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
CA3133162C (en) * 2014-08-12 2024-02-13 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
AU2015331923B2 (en) * 2014-10-17 2020-12-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
JP6737185B2 (ja) * 2015-01-29 2020-08-05 コニカミノルタ株式会社 相互作用する分子を有する血中細胞の同時検出方法
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
BR112017020054A2 (pt) 2015-03-23 2018-06-05 Jounce Therapeutics Inc anticorpos para icos
WO2016162867A1 (en) * 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
JP6609784B2 (ja) * 2015-05-04 2019-11-27 アッフィメッド・ゲー・エム・ベー・ハー 治療のためのｃｄ３０×ｃｄ１６抗体とｐｄ−１アンタゴニストとの組み合わせ
EP3090751A1 (en) * 2015-05-06 2016-11-09 Université de Lausanne Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
SI3322731T1 (sl) * 2015-07-14 2021-03-31 Bristol-Myers Squibb Company Postopek za zdravljenje raka z uporabo imunskega inhibitorja kontrolne točke; protitelo ki veže programiran receptor smrti (PD-1) ali programiran smrtni ligand 1 (PD-L1)
HUE056201T2 (hu) 2015-07-30 2022-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
CA2994631A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US11008391B2 (en) 2015-08-11 2021-05-18 WuXi Biologics Ireland Limited Anti-PD-1 antibodies
WO2017031760A1 (zh) * 2015-08-27 2017-03-02 杨光华 干涉片段及其应用
WO2017031761A1 (zh) * 2015-08-27 2017-03-02 杨光华 干涉片段及其应用
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
ES2895034T3 (es) 2015-10-02 2022-02-17 Hoffmann La Roche Anticuerpos anti-PD1 y procedimientos de uso
RU2729371C1 (ru) 2015-10-02 2020-08-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические к pd1 и tim3
MX2018004177A (es) * 2015-10-08 2018-09-11 Macrogenics Inc Terapia de combinacion para el tratamiento de cancer.
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
WO2017125815A2 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
ES2877568T3 (es) * 2016-02-05 2021-11-17 Orionis Biosciences Nv Agentes de unión de Clec9A
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US20170283496A1 (en) * 2016-03-14 2017-10-05 Roche Innovation Center Copenhagen A/S Oligonucleotides for reduction of pd-l1 expression
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2019000252A (es) 2016-06-30 2019-10-09 Oncorus Inc Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
BR112019002529A2 (pt) 2016-08-09 2019-05-28 Kymab Ltd anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3512563A1 (en) 2016-09-16 2019-07-24 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
CN106480027A (zh) * 2016-09-30 2017-03-08 重庆高圣生物医药有限责任公司 CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA
AU2017339561B2 (en) * 2016-10-07 2024-02-01 Secarna Pharmaceuticals Gmbh & Co. Kg Novel approach for treating cancer
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
KR102606252B1 (ko) 2017-01-09 2023-11-23 테사로, 인코포레이티드 항-pd-1 항체로 암을 치료하는 방법
CA3049656A1 (en) * 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
KR102089371B1 (ko) * 2017-01-26 2020-03-16 사회복지법인 삼성생명공익재단 혈관면역아세포성 t 세포 림프종 진단용 마커 및 이의 용도
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
ES2928718T3 (es) 2017-04-03 2022-11-22 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
HRP20231457T1 (hr) 2017-05-30 2024-05-10 Bristol-Myers Squibb Company Liječenje lag-3-pozitivnih tumora
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CN107253988B (zh) * 2017-07-19 2021-01-29 福州大学 一种人源程序性死亡因子配体pd-l2蛋白的制备方法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
CN107596374B (zh) * 2017-09-01 2020-06-30 广东医科大学 B12蛋白表达抑制剂及其在结核病免疫和治疗中应用
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
CA3089469A1 (en) 2018-01-23 2019-08-01 Nextcure, Inc. B7-h4 antibodies and methods of use thereof
EP3746480A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Bispecific antibodies comprising an antigen-binding site binding to lag3
EA202091810A1 (ru) 2018-03-02 2021-01-29 Файв Прайм Терапьютикс, Инк. Антитела к b7-h4 и способы их применения
CN108530537B (zh) * 2018-03-29 2019-07-02 中国人民解放军军事科学院军事医学研究院 Pd-1/pd-l1信号通路抑制剂
WO2019207942A1 (ja) * 2018-04-27 2019-10-31 OTA Takayo 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
US20210253614A1 (en) 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
EP3843849A1 (en) 2018-08-27 2021-07-07 Pieris Pharmaceuticals GmbH Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN112672759B (zh) * 2018-09-29 2023-05-30 四川科伦博泰生物医药股份有限公司 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
CN110452870A (zh) * 2019-05-20 2019-11-15 河南省肿瘤医院 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
EP3986460A2 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
MA56523A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
US20210154281A1 (en) 2019-11-26 2021-05-27 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
US11673879B2 (en) 2020-03-31 2023-06-13 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
JP2023526250A (ja) 2020-05-13 2023-06-21 マサチューセッツ インスティテュート オブ テクノロジー ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
WO2022165403A1 (en) 2021-02-01 2022-08-04 Yale University Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
WO2023194656A1 (en) 2022-04-08 2023-10-12 Tilt Biotherapeutics Oy Monoclonal pd-l1 antibodies
CN114588258B (zh) * 2022-05-10 2023-04-25 中山大学 Bmp9联合nk细胞和pd-l1抗体在制备肝癌药物方面的应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024040264A1 (en) 2022-08-19 2024-02-22 Massachusetts Institute Of Technology Compositions and methods for targeting dendritic cell lectins
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPS6178686A (ja) 1984-09-26 1986-04-22 Dainippon Printing Co Ltd 真空成形用印刷フイルム
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US6235488B1 (en) 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
EP0711345A1 (en) 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
US5954687A (en) 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
DE19526386C1 (de) 1995-07-19 1997-01-02 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
IL126843A (en) 1996-05-23 2007-06-17 Scripps Research Inst Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
US6103479A (en) 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
NL1008929C2 (nl) * 1998-04-20 1999-10-21 Vhp Ugchelen Bv Uit papier vervaardigd substraat voorzien van een geïntegreerde schakeling.
EP1073720A2 (en) * 1998-04-24 2001-02-07 Hemosol Inc. Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US20030027998A1 (en) 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20060205034A1 (en) 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
PT1137436E (pt) 1998-12-03 2008-09-15 Univ California Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2000055375A1 (en) 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
ATE399793T1 (de) 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
RU2182481C2 (ru) * 1999-08-02 2002-05-20 Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Способ лечения злокачественной лимфомы кожи
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2001014556A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
DE60033530T2 (de) * 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2001021631A2 (en) 1999-09-20 2001-03-29 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
JP5583308B2 (ja) 1999-11-12 2014-09-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２１個のヒト分泌タンパク質
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU2001247401A1 (en) 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
AU2001271731A1 (en) * 2000-06-28 2002-01-08 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
US7238360B2 (en) 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
US6638915B1 (en) * 2000-06-30 2003-10-28 Harold Killam Anti-viral composition
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
EP1328624B1 (en) 2000-09-20 2011-11-09 Amgen Inc. B7-like molecules and uses thereof
US20030180309A1 (en) 2001-01-08 2003-09-25 Baum Peter R. Human B7 polypeptides
WO2002068647A2 (en) 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002245332A1 (en) 2001-01-29 2002-08-12 The Center For Blood Research, Inc Anergy-regulated molecules
WO2002066045A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc. Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
JP4608184B2 (ja) 2001-03-14 2011-01-05 ダコ デンマーク アクティーゼルスカブ 新規なｍｈｃ分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにｍｈｃ分子の使用
WO2002077208A1 (de) 2001-03-27 2002-10-03 Genethor Gmbh Antigen-abhängige reduktion von spezifischen immunreaktionen durch beeinflussung der co-stimulation
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
WO2002092792A2 (de) 2001-05-16 2002-11-21 Genethor Gmbh Antigen-abhängige reduktion von spezifischen immunreaktionen durch beeinflussung der co-stimulation
US20060276422A1 (en) 2001-05-18 2006-12-07 Nassim Usman RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA)
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
GB0116942D0 (en) 2001-07-11 2001-09-05 Sahajanand Biotech Private Ltd Herbal formulation
WO2003006632A2 (en) 2001-07-12 2003-01-23 Canvac Methods and compisitions for activation human t cells in vitro
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
WO2003086459A1 (en) * 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
CA2388441A1 (en) 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
WO2004000221A2 (en) 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
EP2243493A1 (en) * 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
AU2003290083A1 (en) * 2002-08-13 2004-03-11 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas
JP2006512942A (ja) 2002-10-25 2006-04-20 ユニバーシティー オブ コネティカット ヘルス センター 制御細胞溶解による癌の免疫療法のための装置と方法
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ITMI20022758A1 (it) 2002-12-23 2004-06-24 Isagro Ricerca Srl Nuovi uracili ad attivita' erbicida.
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
TW579556B (en) 2003-03-28 2004-03-11 Au Optronics Corp Method of fabricating a low temperature polysilicon film
US20040248205A1 (en) 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
AU2004280630A1 (en) 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Method
WO2005044835A1 (en) 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
US7157434B2 (en) 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
KR20050041296A (ko) 2003-10-30 2005-05-04 학교법인 인제학원 ΗΒｘ 단백질을 발현하는 간세포의 완전한 사멸을유도시키는 방법 및 이 방법을 이용하여 세포사멸 억제물질 및 유전자를 탐색하는 방법
GB0326168D0 (en) 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7304146B2 (en) 2004-01-16 2007-12-04 Applera Corporation Fluorogenic kinase assays and substrates
EP2332538A1 (en) 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
EP1765988B1 (en) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2006007539A1 (en) 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
CN101437964B (zh) 2004-10-18 2012-06-13 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SI2161336T1 (sl) * 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
US7553661B2 (en) 2005-05-31 2009-06-30 Mcgill University Stromal antigen-presenting cells and use thereof
NZ564243A (en) 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP1912672B1 (en) 2005-07-29 2013-09-04 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1934600A2 (en) 2005-09-06 2008-06-25 Kinemed, Inc. Kinetic biomarker for quantification of lymphoproliferation, clonal expansion, recruitment and trafficking in lymphoid tissues and of the in vivo actions of antigens and modulating agents thereon
JP2007089496A (ja) 2005-09-29 2007-04-12 Institute Of Physical & Chemical Research 医薬のスクリーニング方法
MX2008007287A (es) 2005-12-08 2008-10-27 Univ Louisville Res Found Metodos y composiciones para expandir celulas reguladoras t.
MX2008007286A (es) 2005-12-08 2008-10-21 Univ Louisville Res Found Ingenieria in vivo de superficie celular.
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20100015642A1 (en) 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
EP2007806A2 (en) 2006-04-13 2008-12-31 ZymoGenetics, Inc. Tetramerizing polypeptides and methods of use
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
WO2008078673A1 (ja) 2006-12-26 2008-07-03 Japan Science And Technology Agency Ｂ細胞におけるｃｄ２２機能を抑制することから成る免疫応答の促進方法
CN101663323A (zh) 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
WO2008091643A2 (en) 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy
JP2010516786A (ja) 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド ワクチンとしての使用のためのエキソソーム成分の改変
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
JP5140146B2 (ja) * 2010-12-09 2013-02-06 住友ゴム工業株式会社 空気入りタイヤ
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US11111472B2 (en) * 2014-10-31 2021-09-07 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
US10556956B2 (en) * 2015-05-01 2020-02-11 Dana-Farber Cancer Institute, Inc. Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody
CN114272371A (zh) * 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019897A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
KR20180081507A (ko) * 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
EP3922279A1 (en) * 2016-08-30 2021-12-15 Dana Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
WO2019023525A1 (en) * 2017-07-28 2019-01-31 Dana-Farber Cancer Institute, Inc. ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
WO2019089603A1 (en) * 2017-10-31 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods for determining and treating cellular resistance to adp-ribosylating toxin
WO2019232533A1 (en) * 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof

Also Published As

Publication number Publication date
US11359013B2 (en) 2022-06-14
JP2017075168A (ja) 2017-04-20
JP2008543774A (ja) 2008-12-04
SI1907000T1 (sl) 2013-03-29
NZ593388A (en) 2012-08-31
US20160362492A1 (en) 2016-12-15
CA2611861A1 (en) 2006-12-14
JP5882954B2 (ja) 2016-03-09
EP1907000B8 (en) 2013-07-17
NZ601439A (en) 2012-11-30
IL187999A (en) 2015-02-26
CN101355965A (zh) 2009-01-28
RU2007147642A (ru) 2009-07-20
DK2397156T3 (en) 2017-01-09
EP2397156B1 (en) 2016-11-02
PT2397156T (pt) 2016-12-23
NZ564243A (en) 2011-03-31
PL2397156T3 (pl) 2017-07-31
CN103830725A (zh) 2014-06-04
EP1907000B2 (en) 2020-02-26
IL236805B (en) 2018-02-28
IL236806A (en) 2017-06-29
SI2397156T1 (sl) 2017-06-30
RU2596491C2 (ru) 2016-09-10
DK1907000T4 (da) 2020-03-30
EP4242655A3 (en) 2024-02-21
SG10201702670VA (en) 2017-06-29
KR20160029859A (ko) 2016-03-15
US20140178370A1 (en) 2014-06-26
EP3130350A1 (en) 2017-02-15
JP2015187143A (ja) 2015-10-29
JP6494434B2 (ja) 2019-04-03
US10370446B2 (en) 2019-08-06
AU2006254902A1 (en) 2006-12-14
EP1907000A2 (en) 2008-04-09
JP5788632B2 (ja) 2015-10-07
DK1907000T3 (da) 2013-01-28
IL187999A0 (en) 2008-03-20
KR101510065B1 (ko) 2015-04-07
EP1907000B1 (en) 2012-10-17
EP4242655A2 (en) 2023-09-13
EP2397155A1 (en) 2011-12-21
KR101804078B1 (ko) 2017-12-01
IL257622B (en) 2019-12-31
LT2397156T (lt) 2017-02-27
JP5753819B2 (ja) 2015-07-22
CY1118612T1 (el) 2017-07-12
RU2016131170A3 (pl) 2019-12-06
EP2397156A1 (en) 2011-12-21
AU2006254902B2 (en) 2012-04-12
BRPI0611766A2 (pt) 2011-12-20
KR101600225B1 (ko) 2016-03-04
PL1907000T5 (pl) 2020-11-16
WO2006133396A2 (en) 2006-12-14
NZ590308A (en) 2012-02-24
RU2434641C2 (ru) 2011-11-27
RU2011133335A (ru) 2013-02-20
IL257622A (en) 2018-04-30
US20190309065A1 (en) 2019-10-10
US9457080B2 (en) 2016-10-04
KR20140136030A (ko) 2014-11-27
JP2012229213A (ja) 2012-11-22
KR20140043477A (ko) 2014-04-09
ZA200710975B (en) 2023-04-26
CA2981431A1 (en) 2006-12-14
JP2013231054A (ja) 2013-11-14
US8652465B2 (en) 2014-02-18
RU2746383C2 (ru) 2021-04-12
HK1115326A1 (en) 2008-11-28
HUE030877T2 (en) 2017-06-28
ES2397355T5 (es) 2020-11-10
AU2006254902B8 (en) 2012-08-16
AU2006254902A8 (en) 2012-08-16
KR101514463B1 (ko) 2015-04-28
CA2611861C (en) 2017-11-28
EP2397155B1 (en) 2017-12-13
MX351401B (es) 2017-10-13
IL230396A (en) 2017-01-31
RU2016131170A (ru) 2018-02-01
KR20080104254A (ko) 2008-12-02
ES2608316T3 (es) 2017-04-07
US20070122378A1 (en) 2007-05-31
CA2981431C (en) 2021-04-13
CN104436190A (zh) 2015-03-25
WO2006133396A3 (en) 2007-08-09
JP2018109045A (ja) 2018-07-12
SI1907000T2 (sl) 2020-07-31
MX349137B (es) 2017-07-13
ES2397355T3 (es) 2013-03-06
JP2020073527A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
HK1115326A1 (en) Methods and compositions for the treatment of persistent hiv infections by inhibiting the programmed cell death 1 (pd-1) pathway
EP1942948A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
EP1904457A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH
WO2009132785A8 (de) Thiazol-4-carbonsäureester und thioester als pflanzenschutzmittel
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
EP1868628A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POXVIRUS INFECTIONS
IL190547A (en) A medicinal product containing complementary pathway inhibitors for the treatment of ocular diseases
WO2007090623A3 (en) Fungicidal compositions
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
ZA200803493B (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
WO2007015931A3 (en) Caspase inhibitor prodrugs
WO2008049042A3 (en) Ophthalmic compositions containing diglycine
TNSN05197A1 (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation -and immunologically- mediated diseases
WO2008132021A3 (de) Fungizide mischungen
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2008144500A3 (en) 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives
WO2009140101A3 (en) Imidazopyridine compounds useful as mmp-13 inhibitors
WO2005101968A3 (en) Antisense oligonucleotides against cpla2, compositions and uses thereof
WO2008061112A3 (en) Pharmaceutical compounds as inhibitors of cell proliferation and the use thereof
WO2010076564A3 (en) Isochromenones useful in the treatment of inflammation
WO2006084116A3 (en) Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
GB0401964D0 (en) Compositions for use as biocides and biostatics and uses of said compositions
IL182700A0 (en) Compositions for treating and/or preventing diseases characterized by the presesnce of metal ions
IL187889A0 (en) Compositions and methods for preventing or treating hiv infection